Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 734,600 shares, a decline of 38.8% from the October 31st total of 1,200,000 shares. Based on an average trading volume of 6,700,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Performance

NASDAQ APVO traded down $0.07 on Friday, reaching $0.28. 2,663,165 shares of the stock traded hands, compared to its average volume of 3,761,649. Aptevo Therapeutics has a 12 month low of $0.14 and a 12 month high of $10.80. The firm’s fifty day simple moving average is $0.23 and its 200 day simple moving average is $0.40.

Analysts Set New Price Targets

A number of research analysts have recently commented on APVO shares. Roth Mkm lowered their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, September 23rd. StockNews.com began coverage on shares of Aptevo Therapeutics in a research note on Saturday, November 23rd. They set a “sell” rating on the stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.